Out-licensing
Up-to-date access to technology licensing opportunities worldwide.
- Out-licensing
- Browse
Licensing opportunities
These hybrid antibody molecules can be engineered with a variety of small synthetic molecules, and the combination of immunogenic properties results in compounds with powerful target destruction or imaging capabilities. More
potent anti-tumor agents - Antineoplastic Activities of Ellipticine and Its Analogs More
Methods and compositions for making and using functionalized sugars More
An anti-mesothelin antibody of human origin has been generated; it has the ability to efficiently recognize mesothelin on the surface of cells, and induce ADCC in mesothelin-positive cells. More
Two anti-CD22 antibodies of human origin have been generated; each has the ability to recognize CD22 on the surface of Raji cells. More
This technology describes several antibodies, both polyclonal and monoclonal, to the prolactin receptor. More
Immunogenic TARP polypeptides that generate an immune response to breast or prostate cancer cells that express TARP More
These gene chips detect the over-expression of the cancer-related extracellular matrix (ECM) modifier proteins Anakin and Bromodomain 4 (Brd4). More
Adjuvant therapeutic approaches and targets to improve remission in breast and melanoma cancers More
Compositions and methods which employ a combination of monoclonal antibodies which bind to HGF and prevent it from binding to its receptor met in a manner that HGF/met signaling is neutralized More
Related Reports
Market Research Reports provided by reports.iptechex.com
Dec 2010 - 19 pages - $99
Aug 2011 - 8 pages - $75
Aug 2011 - 7 pages - $75
Nov 2010 - 26 pages - $125
Nov 2009 - $15,200
Aug 2011 - 7 pages - $75
Aug 2011 - 7 pages - $75
Aug 2011 - 8 pages - $75
Nov 2011 - 8 pages - $75
Nov 2010 - 40 pages - $500
Your selection
Browse By
- Industry sector
- Antibodies
- Antigens
- Biomarkers
- Cell lines
- Mouse models
- Reagents
- Vectors
- Therapeutic target
- Anti-angiogenesis
- Cancer Antibodies
- Chemotherapy
- Radioimmunotherapy
- Radiotherapy
- Vaccines
- Development phase
- Early Stage
- Preclinical
- Phase I
- Phase I/II
- Phase II
- Phase III
- Phase III/IV
- Preregistration
- Registered
© Copyright 1998-2013 IP Technology Exchange, Inc All rights reserved. Terms and Conditions | Contact us